Analyst Research

Report Title Price
Provider: Directors Deals Ltd.
$12.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Innate Pharma SA Launches 20% Capital Increase


Monday, 18 Nov 2013 01:30am EST 

Innate Pharma SA announced that it plans to launch a private placement dedicated to institutional investors specialized in the Company's business sector, for the amount of approximately EUR 18 million, through the capital increase. The gathered resources are to be spent by the Company on development of products portfolio up to 2017. The capital increase will be realized without preferential subscription rights, the maximum amount of new shares to be issued by the Company is 7.6 million, what reflects approximately 20% of its capital. The Company will file to NYSE Euronext Paris for the admission of newly issued shares to trading. 

Company Quote

8.0
0.08 +1.01%
24 Dec 2014